INTERVIEW: Dong-A Seeks Partners For Global Expansion Push

With a goal of becoming a truly global biopharma firm, Dong-A is now stepping up its R&D efforts like many other leading South Korean pharma companies. In an interview with PharmAsia News, a senior company executive talks about strategies for overseas business development including plans for biosimilars and original new drug candidates.

SEOUL - After completing Phase I clinical trials with its biosimilar versions of Herceptin (trastuzumab) and Aranesp (darbepoetin alfa) in Japan and Europe respectively, Dong-A Socio Holdings is now seeking global partnerships for the two products, possibly reaching deals this year or early next year to proceed with late stage global clinical trials, which will require a hefty amount of funding.

The group is aiming to launch its first biosimilar product, the Herceptin biosimilar, in Japan in 2019, but in the...

More from Focus On Asia

More from Scrip

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.